BioMarin Pharmaceutical vs Neurocrine Biosciences
BioMarin Pharmaceutical reported revenue of $3.2 billion in fiscal 2025, about the same as Neurocrine Biosciences' $2.9 billion in fiscal 2025. BioMarin Pharmaceutical's revenue grew 12.9% in its latest year, and Neurocrine Biosciences' grew 21.4%. BioMarin Pharmaceutical had an operating margin of 12.7%, against 21.6% at Neurocrine Biosciences. Free cash flow was $725 million at BioMarin Pharmaceutical and $749 million at Neurocrine Biosciences.
Side by side
| BioMarin Pharmaceutical | Neurocrine Biosciences | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $3.2B | $2.9B |
| Revenue growth | 12.9% | 21.4% |
| Revenue growth a year, last 5 years | 11.6% | 22.3% |
| Gross margin | 77.7% | 98.2% |
| Operating margin | 12.7% | 21.6% |
| Net margin | 10.8% | 16.7% |
| Free cash flow | $725M | $749M |
| Free cash flow margin | 22.5% | 26.2% |
| Return on capital | 5.8% | 25.6% |
| Net debt to EBITDA | −2.0x | −2.3x |
| Dividends and buybacks | $0M | $168M |
| Change in diluted share count | 0.3% | −1.2% |
| Last close | $55.75 | $145.87 |
| P/E at the last close | 150.7× | 21.4× |
| Insider trades, last 12 months | sold $4.3 million | sold $77.9 million |
| Piotroski F-score | 5 of 9 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
BioMarin PharmaceuticalNeurocrine Biosciences
Operating margin
Percent of revenue
BioMarin PharmaceuticalNeurocrine Biosciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
BioMarin PharmaceuticalNeurocrine Biosciences
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the BioMarin Pharmaceutical and Neurocrine Biosciences pages.